Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Status:
RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.